Related Experiment Videos
Pharmaceutical design and development of a Sinemet controlled-release formulation
R E Dempski1, E C Scholtz, E R Oberholtzer
1Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Neurology
|November 1, 1989
Summary
A monolithic matrix tablet containing carbidopa-levodopa was selected as the most effective controlled-release dosage form for Sinemet CR. This formulation ensures optimal drug release through surface dissolution and erosion, confirmed by extensive testing.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Pharmacokinetics
Background:
- Various formulation techniques exist for developing controlled-release dosage forms.
- Optimizing drug delivery for medications like Sinemet CR (carbidopa-levodopa) is crucial for therapeutic efficacy.
Purpose of the Study:
- To evaluate and select the most suitable controlled-release delivery system for Sinemet CR.
- To identify a formulation that ensures effective release of both carbidopa and levodopa.
Main Methods:
- Evaluation of five different erosion-controlled or diffusion-controlled delivery systems.
- Selection based on extensive in vitro testing, pharmacokinetic studies, and clinical trials.
- Characterization of the chosen monolithic matrix tablet formulation (carbidopa-levodopa 50-200 mg).
Main Results:
- A monolithic matrix tablet utilizing surface dissolution and erosion was identified as the optimal system.
- The selected Sinemet CR formulation demonstrated a 1st-order release rate for both carbidopa and levodopa.
- In vitro release rates correlated with plasma levels; slower release resulted in lower levodopa plasma concentrations.
Conclusions:
- The monolithic matrix tablet represents the most effective controlled-release formulation for Sinemet CR.
- This formulation ensures predictable drug release kinetics, optimizing therapeutic outcomes.
- Understanding the relationship between in vitro release and in vivo pharmacokinetics is key for controlled-release design.